Xencor, Inc. develops engineered antibody therapeutics for cancer and autoimmune diseases using its XmAb technology platform and related antibody-engineering formats. News about XNCR commonly covers clinical and preclinical updates for XmAb drug candidates, including TL1A programs such as XmAb942 and XmAb412, T-cell engaging bispecific antibodies such as XmAb819 and XmAb541, and presentations of data at medical meetings.
Recurring company updates also include quarterly financial results, research-and-development priorities, collaboration and licensing activity, intellectual-property developments tied to Xtend Fc domain technology, and royalty matters involving partner-marketed medicines such as Ultomiris.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.